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Abstract: The chemical diversity associated with marine natural products (MNP) is 
unanimously acknowledged as the ―blue gold‖ in the urgent quest for new drugs. 
Consequently, a significant increase in the discovery of MNP published in the literature has 
been observed in the past decades, particularly from marine invertebrates. However, it 
remains unclear whether target metabolites originate from the marine invertebrates themselves 
or from their microbial symbionts. This issue underlines critical challenges associated with 
the lack of biomass required to supply the early stages of the drug discovery pipeline. The 
present review discusses potential solutions for such challenges, with particular emphasis 
on innovative approaches to culture invertebrate holobionts (microorganism-invertebrate 
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assemblages) through in toto aquaculture, together with methods for the discovery and 
initial production of bioactive compounds from these microbial symbionts. 
Keywords: marine natural products; aquaculture; microbial symbionts; marine 
invertebrates; pharmaceuticals 
 
1. Introduction 
Marine ecosystems harbor a substantial fraction of Earth’s biodiversity and provide a wide range of 
goods and services [1]. Among these, marine natural products (MNP) have received special attention 
in recent years. The main driver for this particular focus on MNP was the urgent need for new 
chemical diversity to fuel the drug discovery pipeline. This impulse led to a major increase in the 
discovery of MNP in the past decades [2,3], with over 20,000 new compounds described since the 
1950s [4]. A large fraction of these new metabolites were obtained from marine invertebrate species [2], 
which make up about 50% of all extant non-microbial marine biodiversity in the oceans [5]. Although 
success stories of marine derived-drugs are already a reality [6], the true potential of MNP from 
invertebrates as future drug candidates is yet to be unraveled [7,8]. However, one critical issue usually 
associated with the initial steps of marine drug discovery from invertebrates is the lack of a constant 
and reliable supply of animal biomass [9]. Relevant to this supply problem is the realization that 
symbiotic microorganisms, including protists, may, in fact, synthesize a large number of metabolites 
once considered to be produced by marine invertebrates [9–12]. 
The present review addresses the potential of MNP derived from microorganisms-invertebrate 
assemblages and the production of the target metabolites for the initial steps of drug discovery. This 
work focuses on in toto aquaculture of invertebrate holobionts, i.e., the invertebrate host and the 
associated community of microorganisms, as well as on culture-dependent and independent strategies 
for the isolation of bioactive compounds from microbial symbionts for drug discovery. Although 
aquaculture for drug discovery is still an emerging field, particular emphasis is also given to the 
manipulation of culture conditions that may contribute toward maximizing the production of microbial 
symbionts and their secondary metabolites. 
2. Marine Microorganism-Invertebrate Assemblages 
Marine invertebrates are a source of high microbial abundance and diversity (e.g., [13–15]). For 
instance, the number of bacteria in sponges may exceed bacterial concentrations in seawater by two to  
four orders of magnitude [16]. Cnidarians, especially corals, also harbor an impressive number of 
microbial organisms; for example, the coral mucus may reach microbial concentrations 100- to  
1000-fold higher than those observed in seawater [17]. Invertebrate microbial symbionts are also 
highly diverse [18]. The abundant and unique symbiotic microbial diversity hosted by marine 
invertebrates [18,19] plays a very important role in their biology and ecology, particularly in its 
nutrition [20–22], disease-resistance [13,17] and response to environmental perturbations [23,24]. 
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Symbiotic microorganisms are also known to be active players in the chemical mediation of 
interactions among marine organisms [25]. 
Marine microbial symbionts have been recognized for their active role in chemical defenses of 
marine invertebrates against both predators and competitors [25–27]. The symbionts produce chemically 
diverse and biologically active secondary metabolites, such as anti-inflammatory, antibiotic, antitumor, 
anticancer, antibacterial and antifungal compounds, whose properties are particularly interesting for 
drug discovery [6,11,28]. The microbiome of marine invertebrates may represent a remarkable 
proportion of the holobiont biomass. In sponges, for instance, the microbial community may contribute 
up to 60% of the holobiont biomass [29]. Contrastingly, in other invertebrates, such as scleractinian 
corals, symbiotic microorganisms are highly abundant in the soft tissue of the host, but represent a 
minor fraction of the total biomass, due to the weight that their hard calcium carbonate skeleton 
represents [30]. However, regardless of microbial abundance, the compounds produced by symbiotic 
microorganisms of marine invertebrates with potential for drug discovery are usually secondary 
metabolites. As such, these compounds are naturally produced in low quantities. This imposes critical 
challenges to the drug discovery pipeline, particularly during the early phases of discovery and the 
selection of which leads should advance to the next step [31–33]. 
3. The Supply Problem in Marine Drug Discovery 
While in the past, the search for new MNP heavily relied on the harvesting of wild specimens and 
large quantities of animal biomass were needed to screen for new chemical diversity, nowadays, small 
amounts of tissue from a single individual can be enough for an initial screening [32,34]. Nonetheless, 
this dependence on natural samples may still entail replicability issues [32]. Wild marine organisms 
collected for bioprospecting are exposed to environmental variability, as well as changes at the 
community level, which may significantly affect their chemical ecology [35]. Individuals of the same 
species sampled in different areas, or time frames, may not display the same chemical composition [36] 
and, therefore, fail to guarantee the supply of a target metabolite (a pitfall commonly termed ―loss of 
the source‖). This may also be a potential caveat for the initial detection of bioactive metabolites, as 
environmental and individual variability in the chemical composition of target organisms may bias 
bioprospecting [32]. Also associated with replicability issues is the potential loss of the source through 
extinction of target species. This issue is particularly relevant in the oceans of today and tomorrow, as 
vulnerability to extinction in marine ecosystems is predicted to be higher on tropical coral reefs [37,38], 
which have been bioprospecting hotspots since the 1990s [2]. 
The relatively low natural abundance of bioactive metabolites that is often recorded in marine 
invertebrates [39] is not a constraint for the initial steps of the drug discovery pipeline, as only small 
amounts of biomass are currently required. However, while the amount of pure compound required for 
screening an isolate is usually lower than 1 mg, an increase in several orders of magnitude of target 
compound quantity (e.g., a few g) is needed to progress satisfactorily towards preclinical trials [34]. 
Once the compound proceeds through clinical trials and is commercialized as a pharmaceutical, 
kilograms of the pure compound are required to supply drug production, which may correspond to an 
annual capture or production of several tones of the invertebrate holobiont [33,34]. Overall, the 
challenges associated with the harvest/culture of target organisms to yield either milligrams, grams or 
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kilograms of a given pure compound inevitably triggers supply issues that only escalate as the 
compound progresses into later development stages of the drug discovery pipeline [40]. Therefore, the 
production of these compounds at a scale large, enough to fulfill the needs of drug discovery and 
potential commercial applications, has been a major issue [6,40] that has prompted innovative 
solutions. To overcome the ―supply problem‖, current R&D strategies of the pharmaceutical industry 
are largely associated with the development of synthetic or hemisynthetic analogues and the use of 
heterologous gene expression techniques [41], as well as with the design of molecules displaying a 
lower complexity and a similar bioactive function that can be synthesized using standardized 
techniques [33,42]. However, there are several constraints associated with these approaches. The 
remarkable complexity of certain natural molecules (most are chiral and display intricate structures) 
makes it very difficult, and often impossible, to replicate the natural molecule in the laboratory [40,43]. 
Furthermore, the large number of steps often required to produce such synthetic analogues, together 
with the notable number of misassigned products, commonly represent an extreme financial burden 
that most drug discovery companies are unable to support [44]. Hypothetically, even if chemical 
synthesis was a technically feasible option, the production of the target metabolite at the kilogram 
scale would probably not be affordable for commercial applications [45]. While heterologous gene 
expression is a very useful and promising technique for drug discovery from symbiotic 
microorganisms [31], it is important to note that target genes from source organisms might not be 
expressed in all hosts, and therefore, developing such an assay for new species requires considerable 
efforts. Moreover, the target gene from the symbiotic microorganism may need a cue to trigger its 
expression, such as the influence of other community members, or share a metabolic pathway with its 
invertebrate host [46]. 
It is therefore undeniable that the ―supply problem‖ is at the center of the main constraints 
impairing drug discovery from the marine environment and is usually strongest at the early stages of 
drug development [6,32,40]. This issue becomes even more relevant when target compounds are 
produced by symbiotic microbes due to the low levels at which these metabolites are produced, along 
with the smaller proportion that microbial biomass commonly represents when compared to the 
majority of their invertebrate hosts [10,11,31]. Nevertheless, the interest in the remarkable properties 
of MNP remains appealing enough to inspire innovative solutions to the supply problem [6].  
The in toto aquaculture of the holobiont [47] and the culture of symbiotic microorganisms present in 
the microbiome of invertebrates [48] are certainly promising approaches to find potential solutions for 
such bottlenecks. 
4. Aquaculture of Marine Invertebrates 
Current aquaculture practices can be broadly classified as in situ or ex situ. This terminology is 
mostly associated with the production site. In situ aquaculture, also known as mariculture, is the 
culture of organisms in the marine environment using natural conditions. Ex situ aquaculture is the 
process of producing organisms in a controlled environment. Both have advantages and disadvantages 
(Figure 1). In situ aquaculture entirely relies on natural conditions (water physical and chemical 
parameters, water flow, current and hydrodynamics, light and nutrients) required for the propagation 
and growth of the target species and requires no adaption to an artificial propagation system. However, 
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cultured species can be potentially exposed to several deleterious factors present in the natural 
environment, such as sedimentation, unfavorable meteorological conditions, predators, parasites, 
competitors and other natural hazards, which can reduce survival and growth [49]. Human resources 
play a major role in the assemblage and maintenance of infrastructures, with the most manpower being 
necessary to kick-off the culture process and to harvest cultured specimens at the end of production 
cycles. The ability to manipulate culture conditions is, however, fairly limited, as the largest allowed 
flexibility is the selection of the location where production structures are implemented. This decision is 
extremely important, as different areas may display contrasting environmental conditions and thus 
affect the success of in situ aquaculture [50]. In contrast, ex situ aquaculture requires a more skilled 
work force and has higher costs associated with the building and operation of culture facilities. 
Nonetheless, the ability to manipulate biotic and abiotic factors to maximize animal biomass and 
metabolite production is incomparably higher than that for in situ aquaculture. Ex situ aquaculture 
allows the use of optimized husbandry methodologies specifically designed for the target species being 
produced. Additionally, and unlike in situ aquaculture, ex situ production prevents the risks of genetic 
pollution of natural populations associated with the mass culture of single genotypes in the wild [51]. 
Nonetheless, ex situ aquaculture techniques may also have impacts on the natural environment, which 
should be prevented or minimized through proper regulation of effluents that may be loaded with 
nutrients and chemicals used for therapeutic purposes and water-quality management [52]. However, it 
should be noted that ex situ aquaculture of invertebrates for non-food purposes often uses recirculation 
techniques specifically designed to minimize the discharge of waste water. 
Despite the technological simplicity of production in situ and the correspondingly expected low 
production costs, this approach has proven to be more technically challenging and expensive than 
previously assumed for supporting drug discovery [53]. While incurring higher production costs and 
requiring skilled workers for the implementation and maintenance of production systems, ex situ 
aquaculture can be implemented in privileged locations, such as in the vicinity of pharmaceutical 
laboratories; this physical location can ensure a more rigorous processing after the harvesting of 
produced specimens and, thus, avoid costs associated with paperwork, handling, packaging, shipping 
and spoilage during the transport of produced biomass. 
The drawbacks associated with in situ aquaculture (Figure 1) may be overcome through ex situ 
aquaculture in controlled environments, which may eliminate problems commonly faced by 
researchers, such as the loss of the source and reproducibility. Additionally, in ex situ cultures, 
environmental conditions can be manipulated, optimized and stabilized to: (i) accelerate the growth of 
cultured species; (ii) ensure the presence of symbiotic taxa in the invertebrate host that are known to be 
important producers of the target compound (e.g., Aspergillus spp. in sponges) [54–57]; (iii) increase 
or decrease the number of symbionts according to their relevance in metabolite production; and (iv) 
adjust the biotic and/or abiotic settings that ensure the maximum yield of the target bioactive  
compounds [58]. Ex situ aquaculture further allows better control of the genetic selection of the target 
species, which ultimately leads to the optimization of culture conditions for particular genotypes that 
may yield higher metabolite production. Specific genotypes may also hold contrasting microbial 
communities with different metabolite production. 
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Figure 1. SWOT analysis (strengths, weaknesses, opportunities and threats) of the  
in situ and ex situ aquaculture of marine invertebrates for marine drug discovery  
and development. 
 
The use of aquaculture for drug discovery is still in its infancy, and in toto production of marine 
organisms is a process that deserves greater attention from researchers aiming to produce the biomass 
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of secondary metabolites [47]. The use of controlled environments ex situ can minimize environmental 
variability that affects the chemical ecology of the holobiont and, consequently, contributes to 
achieving a higher degree of replicability. This feature is of paramount importance to maintain a stable 
community of bioactive metabolite-producing symbiotic microorganisms in the invertebrate host. 
Furthermore, as previously mentioned, culture protocols may also be optimized to continuously provide 
animal/microbial biomass and maximize target metabolite production [58]. 
The following sections focus on aquaculture practices of different invertebrate groups and the 
optimization of culture protocols that can maximize symbiont biomass and metabolite production, with 
emphasis on successful case studies. The invertebrate groups emphasized here are sponges, cnidarians, 
mollusks, as well as a few other taxa relevant for drug discovery (e.g., bryozoans, tunicates and 
worms). This selection is based on the importance of these groups in MNP discovery [2], as well as on 
ongoing efforts to address the aquaculture of these marine invertebrate groups [59–62]. 
4.1. Sponges 
For many years, sponges (Porifera) have been regarded as the primary target for MNP discovery [2]. 
Sponges illustrate the supply issue at its best, as their MNP are biochemically complex (i.e., difficult 
targets for chemical synthesis) and are often present only in minute quantities in animal tissues. 
Sponges are also known to host a large and diverse community of microorganisms [63], which can 
compose a notable fraction of the sponge tissue volume [16]. Such symbiotic microorganisms may 
display interesting bioactivities as new drug leads. For instance, marine-derived fungi, such as 
Aspergillus ustus and Petriella sp., were isolated from the sponge, Suberites domuncula, and yielded 
cytotoxic sesquiterpenoids that have anticancer applications [64,65]. Moreover, bacteria within the 
genera, Aquamarina, Pseudovibrio and Streptomyces, displaying anti-fungal and anti-bacterial activity, 
were isolated from the sponges, Amphilectus fucorum and Haliclona simulans [66]. 
Many sponge species with the potential for drug discovery are not available in large quantities in 
nature, and sponges are notoriously difficult to culture [67]. A well-known example is the anticancer 
compound, halichondrin B, isolated from Halichondria okadai, which is now a drug (Halaven
®
) and 
was based on a synthesis of the active end following an initial biomass supply from New Zealand, with 
the original compound being present in quantities lower than 1 mg∙kg−1 of wet sponge biomass [41]. 
This example clearly shows that reliable methods for the production of sponge materials are desired to 
fully explore the possibilities that sponge MNP have to offer. 
Scientists have substantially increased their efforts to develop culture techniques for marine 
sponges, which include in situ aquaculture (reviewed by [68]) and ex situ culture approaches, such as 
aquarium culture, primmorphs and cell cultures (reviewed by [67,69]). While sea-based culture 
techniques (Figure 2) have proven to be feasible for products, such as halichondrin [70], avarol [61] 
and discodermolide [71], ex situ approaches have not yet been very successful, mostly due to the lack 
of scientific knowledge on sponge biology. Sponges have a high potential for growth, but release most 
of their productivity through the shedding of cellular materials into the environment [72–76]. 
Apart from general methodological issues, such as choices of culture materials, site selection, 
cutting methods and explant sizes, recent studies have also included more advanced aspects, such as 
heredity [68]. A clear genotype-associated difference in performance (i.e., growth and metabolite 
Mar. Drugs 2014, 12 3936 
 
 
production) was observed for Discodermia dissoluta [71]. Such genotypic differences suggest that 
broodstock optimization through genotypic selection can help increase sponge mariculture 
productivity. Notwithstanding this, negative effects of repetitive cloning have been reported [49], 
which may counteract the benefits of genotypic selection. Future studies are therefore required to 
further elaborate on this aspect. 
Most sponges in mariculture retain their ability to produce the compound of interest [49,50,71,77–79]. 
Cultured explants of Discodermia dissoluta even contained higher amounts of discodermolide than 
their wild conspecifics [71]. Attempts to enhance secondary metabolism in mariculture included  
stress treatments, which were successfully applied to increase the production of avarol [80] and 
latrunculin B [81]. Other factors reported to influence metabolite concentration include location, depth 
and seasonality [82,83]. 
Figure 2. Examples of Mediterranean sponges in sea-based aquacultures. (A) Culture 
frame with spike-cultures of Dysidea avara, as described in Osinga et al. [78]. In addition, 
many sponges primarily feed on dissolved organic carbon (DOC) rather than being particle 
feeders [72–75], which has altered the view on designing feeding regimes for sponges in 
aquaria; (B) Detail of D. avara growing on spikes; (C) Culture of Chondrilla nucula on 
vertical plates. Images by M. Gokalp and R. Osinga. 
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4.2. Cnidarians 
Cnidarians have become the second most bioprospected group of marine invertebrates [2].  
Besides the bioactive metabolites associated with cnidarians [7], there are also important metabolites 
produced by symbiotic microorganisms associated with corals, such as the fungi, Nodulisporium sp. 
and Zygosporium sp., associated with unidentified corals (reviewed by [84]), Vibrio species  
isolated from the soft coral, Sinularia polydactyla [85], Chondrostereum sp. isolated from the  
soft coral, Sarcophyton tortuosum, and Aspergillus versicolor from the soft coral, Cladiella sp.  
(reviewed by [86]), among others. Despite the remarkable chemical diversity and potential for drug 
discovery displayed by this group of invertebrates, to the best of our knowledge, no metabolite from 
cnidarians has yet reached the pharmaceutical clinical pipeline, i.e., entered clinical trials or obtained 
approval for commercialization. 
Most efforts on cnidarian aquaculture have been focused on corals (e.g., [87,88]) and sea anemones 
(e.g., [89]). Studies on in situ production methods have primarily focused on asexual propagation 
through fragmentation [90] and the selection of the area for the grow-out of coral fragments [91–93].  
The ex situ culture of cnidarians is usually performed in tanks with controlled environmental settings: 
physico-chemical parameters, water flow, light spectra and intensity, as well as feeding. All of these 
parameters are critical to maximize survival, nutritional/physiological condition and growth [62,89,94–99]. 
Micropropagation techniques have also been developed and create progeny from tissue explants 
derived from a single polyp of colonial corals [100]. Sexual reproduction of cnidarians is becoming 
increasingly popular as a method for the production of a large number of organisms, particularly  
corals [101]. However, research efforts on coral sexual reproduction have been targeting reef restoration 
and management of captive populations [102,103]. 
Environmental factors, such as light [58], are important drivers of metabolite production in 
cnidarians. To our knowledge, only a single study assessed the effect of light intensity on metabolite 
production (flexibilide) by the soft coral, Sinularia flexibilis [58]. The use of herbivorous fishes in the 
production tanks may also contribute to the production of secondary metabolites that cnidarians use as 
chemical defense mechanisms [104]. Furthermore, the polyculture of different cnidarian species within 
the same tank may also induce metabolite production. For instance, chemical extracts from the stony 
coral Tubastraea faulkneri kill larvae of other coral species [105]. Thus, the combination of different 
coral species, either stony or soft corals, is likely to trigger the production of bioactive metabolites, but 
may also induce coral mortality [106]. 
Specimen selection is also an important factor to consider, as the production of secondary metabolites 
may show sex-specific and inter-clonal variability [106]. Genotypic differences may also affect the 
composition of the associated microbiota. Symbiotic microorganisms are mainly present in the soft 
tissue and/or mucus produced by cnidarians, and therefore the increase of the proportion of soft tissue 
and mucus to the total holobiont biomass may represent a significant increase in the yield of the target 
metabolite for drug discovery. Although the drivers of coral tissue growth are still poorly investigated, 
it is known that heterotrophic feeding maximizes coral tissue growth [96,107] and that mucus 
production is associated with protection from UV, desiccation and increased sediment loading [108]. 
While cnidarian aquaculture is already an established technology that allows the production of 
monoclonal organisms [89,99], it has hardly been applied for drug discovery research. Nevertheless, 
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production costs are likely to be affordable to pharmaceutical companies [99] and may even decrease 
with the use of new technologies, such as LED illumination, that have a lower energetic consumption [96]. 
Ex situ culture systems may also be used to either keep a live library of cnidarians and its associated 
microbial community or to produce the target organism synthetizing the desired metabolite. 
4.3. Mollusks 
Approximately 1100 distinct compounds have been isolated from less than 300 species of mollusks, 
and most of them have been isolated from gastropods [4]. The origin of their NP has been attributed to 
their ability to bio-accumulate or biotransform molecules acquired through feeding [109], de novo 
synthesis [110] and bacterial symbionts [33]. While some mollusk species are protected by shells and 
an arsenal of peptide toxins, they also host symbiotic bacteria that contribute to their chemical 
defenses, a feature that holds great interest for marine drug discovery [111]. Shell-less mollusks, such 
as the sacoglossans, Elysia spp., also associate with a number of bacteria that provide chemical 
defense, which are usually found in their gut and mucus [112,113]. Such mollusks have also been an 
important source of a very potent class of cytotoxic peptides—the kahalalides [114,115]. For example, 
cyanobacteria of genera Symploca and Lyngbya associated with the aplysiid Dolabella auriculata 
produce Dolastatin 10, an antimicrobial peptide [116,117] that is currently in phase II clinical trials as 
an anticancer agent [118]. Bacteria, such as Mycoplasma spp. and Vibrio spp., that are known to 
associate with the sacoglossan, Elysia rufescens, produce elisidepsin (Irvalec
©
), another cyclic peptide 
belonging to the kahalalide family that is currently under phase II development [43]. Actinomycetes 
represent another example of biochemically interesting symbionts from mollusks. Actinomycetes 
living in close association with cone snails (Conus spp.) contribute to the production of conotoxins, 
which are peptide-based neurological toxins with analgesic properties [119–122]. Ziconotide (Prialt®), 
the synthetic equivalent of a naturally occurring 25-amino acid peptide (ω-conotoxin MVIIA) derived 
from the venom of a predatory cone snail, was the first marine drug to be approved for clinical use [122] 
to treat chronic pain. Kurasoins, soraphinol C and other molecules with important neuroactive 
biological properties have also been isolated from three different species of cone snail (Conus rolani, 
C. pulicarius and C. tribblei) [123,124]. 
Although the supply problems of these success stories have been mostly overcome through the 
chemical synthesis of target molecules, many more metabolites from mollusks and their symbiotic 
microbiota could be on a more advanced stage of the drug discovery pipeline if the supply issue were 
solved, particularly at the initial steps of drug discovery. 
In situ aquaculture of mollusks has been widely applied to bivalves for food production [125]. 
Although there were a few NP discovered in marine bivalves [2], there are still no endeavors 
developing the in situ aquaculture of bivalves for drug discovery. As opposed to bivalves and in 
contrast to other invertebrate groups, such as sponges and cnidarians, most efforts toward the 
aquaculture of gastropods have been undertaken ex situ. While new advances have been achieved in 
the last decades in the larviculture and grow-out of marine snails for human consumption and 
restocking purposes (e.g., [126,127]), large-scale production for biotechnological applications is yet to 
be addressed. Sea slug production is still restricted to Aplysia californica, which is a widely used 
model organism in neurosciences research [128]. Nonetheless, recent data using small-scale 
Mar. Drugs 2014, 12 3939 
 
 
recirculating culture systems opens good perspectives for the production of several other sea  
slug species and their associated microbiota [60]. The most important environmental parameters  
to successfully culture sea slugs are associated with water physico-chemical parameters  
(e.g., temperature, pH, light cycle) and nutrition [129–131]. 
4.4. Other Invertebrates 
Bioprospecting efforts targeting marine invertebrates have clearly been biased towards sponges and 
cnidarians [2]. Nonetheless, other groups of marine invertebrates, such as bryozoans, tunicates and 
nemertine worms, have also yielded promising compounds to fuel drug discovery programs. For 
example, one pharmaceutical already being commercialized (Yondelis
®
) was inspired from trabectedin, a 
secondary metabolite from the tunicate, Ecteinascidia turbinata, whereas the NP plitidepsin 
(Aplidin
®
), described as being from the ascidian (tunicate) Aplidium albicans, is now under clinical 
evaluation [132]. Moreover, 3-(2,4-Dimethoxybenzylidene)-Anabaseine (DMXBA; also called GTS-21) 
is an anabaseine derivative from the hoplonemertine worm, Amphiporus lactifloreus, that is in clinical 
development to treat Alzheimer’s and schizophrenia [133]. It is also worth highlighting that both 
tunicates and bryozoans have already been targeted by aquaculture efforts aiming to supply drug 
discovery [134]. 
The bryozoan Bugula neritina has been the focus of pharmaceutical companies due to its NP 
bryostatin 1, an antineoplastic agent [135]. The first aquaculture efforts for this species employing an  
ex situ approach failed, due to the lack of adequate food provisioning and a constant larval supply [53]. 
The latter prompted the collection of mature wild organisms to spawn in the laboratory [136] and the 
improvement of culture protocols [137]. Asexual reproduction of bryozoans through fragmentation, as 
previously described for corals, has also been described [138]. Issues associated with constant and 
reliable ex situ production promoted the development of in situ culture approaches [53,136],  
which were successfully employed to produce this bryozoan and yield bryostatin 1 within the normal 
range for ocean populations (average 7.5 μg/g dry weight) [136]. It is further important to note the 
important role played by symbionts in the biosynthesis of other bioactive metabolites in bryozoans.  
B. neritina is one of the best-documented examples of bioactive metabolite symbiosis, and other 
bryostatins discovered in this bryozoan species are, in fact, biosynthesized by its bacterial symbionts 
(reviewed by [139]).  
The tunicate, E. turbinata, also represents an interesting case study for aquaculture. Its most potent 
NP, trabectedin, is present at very low yields (0.0001%), resulting in nearly 1 ton of animal biomass 
being required to isolate 1 gram of this compound [39,140]. Initial aquaculture efforts were performed 
both in situ (using PVC structures with ropes where lab-settled colonies were attached) and ex situ  
(in tanks) [136]. During the development of Yondelis
®
, the developing enterprise addressed the supply 
problem with both in situ and ex situ aquaculture. This approach allowed them to pursue the clinical 
development of the drug, but aquaculture was revealed to be unfeasible for commercialization due to 
high production costs and low metabolite yield [140]. 
These two case studies highlight the importance that aquaculture may play in the production of 
metabolite biomass from bryozoans and tunicates for drug discovery, at least in the early steps of the 
discovery pipeline. Although these NP (bryostatin 1 and trabectedin) are produced by the invertebrate 
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host, aquaculture practices may also be used to yield metabolites produced by symbiotic organisms [31]. 
It is also important to note that the aquaculture of B. neritina and E. turbinata has mostly been focused 
on the maximization of biomass production, without any effort to manipulate culture conditions that 
may increase the production of target metabolites. Stress experiments may contribute toward 
understanding the drivers of secondary metabolite production and optimizing aquaculture protocols to 
magnify the yield of target molecules [53,58]. 
5. Discovery of Bioactive Compounds from Marine Invertebrate-Associated Microorganisms and 
Their Production 
The isolation of a pure culture of target microorganisms can be extremely challenging and is often a 
necessary step in the drug discovery pipeline [141]. Traditionally, microorganisms can be cultivated 
through serial plating on selective growth media. However, when using these techniques, only  
0.001%–1% of the total microbial diversity can be successfully cultivated [142]. These numbers are 
certainly far from providing an acceptable overview of the microbial landscape of the source 
environment [143]. When comparing marine and terrestrial environments, the first is highly unstable, 
heterogeneous and oligotrophic. These conditions make the marine environment particularly difficult 
to mimic for the cultivation of marine microbes. Some of the constraints that researchers have to face 
when addressing this issue include: (i) the inability to reproduce highly complex nutritional and 
environmental conditions, as well as complex networks of cell-cell interactions (e.g., metabolites 
exchange and signaling); (ii) the overgrowth of slow- by fast-growing microorganisms; (iii) viral 
infections; and (iv) insufficient time allowed for growth [47,142,143]. 
Recent breakthroughs have allowed the cultivation of microorganisms previously labeled as 
unculturable [144]. Initial attempts consisted in optimizing traditional cultivation methods through 
modifications of culture media (e.g., carbon sources, electron acceptors, nutrient concentration) and 
growth conditions (e.g., inoculation size, temperature, pH, incubation time) [144,145]. For example, 
the use of low substrate/nutrient concentrations combined with extended growth time has allowed the 
cultivation of formerly unculturable bacteria from the taxa Verrucobacteria, Actinobacteria, Acidobacteria 
and Proteobacteria [146]. Such optimizations of culture conditions and media have allowed significant 
increases in the propagation of microbial colonies of the culturable fraction of bacteria [147]. 
However, successful microbial development generally requires interactions between microbes and 
their environment (i.e., their invertebrate host for microorganism-invertebrate assemblages), as well as 
with other members of the community. Such interactions include the exchange of metabolites and 
signals (chemical cues), which is incompatible with traditional pure culture isolation methods [148]. 
New techniques developed to overcome this issue consist of simulating the conditions of the source 
environment, either through co-culture (simulating microbial interactions) or in situ cultivation 
(simulating both environmental conditions and microbial interactions).  
The co-culture approach, which allows the development of colonies of microorganisms generally 
able to grow only in combination with other microbes, has led to the successful isolation and/or 
enrichment of several previously unculturable microorganisms (e.g., [149,150]). However, while these 
techniques allow interactions between different members of the cultured communities, they do not 
simulate/provide other variables of the source environment. A variety of in situ cultivation techniques 
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based on diffusion chambers and encapsulation have been proposed in order to fill this gap  
(see [143,144,147] for a review). Systems based on diffusion chambers have been developed in diverse 
varieties (e.g., [151–153]) and allow communication between the cultured organisms and their 
environment. Although initial model systems [153] were labor-intensive and low-throughput, the 
methods developed subsequently were much more efficient and allowed the simultaneous in situ 
cultivation of micro-colonies in up to 96 [152] or 384 [151] diffusion chambers. This approach 
resulted in the culture of a significantly higher microbial diversity than that commonly achieved using 
―traditional‖ techniques [154]. 
An alternative technique, initially developed by Zengler et al. [141], involves the high-throughput 
cultivation of microorganisms individually encapsulated in agar gel microdroplets (GMDs). While this 
method was particularly appropriate for the cultivation of slow-growing organisms, as they were 
protected from overgrowth by fast-growing organisms, the lack of protection from the environment 
prevented its use for incubation in situ [48]. Ben-Dov et al. [48] proposed an improvement on GMDs 
by encapsulating similar agar spheres in a polysulfonic polymeric membrane permeable to nutrients 
and cues from the environment. This ―double encapsulation‖ technique allows for cell-to-cell 
interactions and exchanges between the microorganisms and their environment and resulted in the 
successful in situ isolation of previously unidentified microorganisms, including bacteria, fungi  
and stramenopiles [48]. 
Whereas the in situ cultivation techniques described above are extremely promising, much of the 
microbial diversity remains to be explored, leaving untapped a huge array of secondary metabolites 
potentially useful for the development of new drugs. Culture-independent methods may help fill this 
gap in a variety of ways. Metagenomics can be used to express genes from environmental DNA 
samples in appropriate vectors, which can then be screened for new compounds of interest through 
sequence mining or functional expression [155]. Such heterologous gene expression has been successfully 
used to produce bioactive compounds of pharmaceutical interest from marine organism-associated 
microbial symbionts, thereby proving the potential of this technique for culture-independent production 
of bioactive compounds. For example, patellamides A and C, promising compounds for their moderate 
cytotoxicity and potential to reverse multidrug resistance produced by Prochloron didemni, a 
cyanobacterial symbiont of the marine ascidian, Lissoclinum patella, have been produced through 
expression in Escherichia coli [156,157]. Furthermore, techniques, such as immunofluorescent 
viability screening and micromanipulation, may improve the efficiency of microbial cultivation [144].  
Finally, with the development and increasing affordability of new sequencing technologies, whole 
genomes/transcriptomes and proteomes from microorganisms may be sequenced and subsequently 
mined for new bioactive metabolites or to provide relevant information for the development of 
successful culture methods [155]. 
The range of both culture-dependent and independent approaches available for the discovery and 
high-throughput production of new bioactive compounds from symbiotic microorganisms provides 
excellent prospects that the true potential of these metabolites for drug discovery may soon be 
unveiled. Together, these methods may allow marine invertebrate symbionts to provide a steady and 
sustainable supply of bioactive secondary metabolites to fuel the next generation of MNP.  
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6. Future Prospects 
The production of biomass of marine invertebrate-microorganisms assemblages through in toto 
aquaculture is a potential solution to some of the critical challenges that the pharmaceutical industry 
has been facing in order to find a constant and reliable supply of biomass to fuel the marine drug 
discovery pipeline. Ex situ aquaculture provides a stable environment and allows the application of 
specific stressors/effects that may trigger metabolic reactions in the microbiota associated with marine 
invertebrates and promote higher yields of target metabolites. It is important to stress that although 
aquaculture is not the final solution to solve the ―supply issue‖ in marine drug discovery (from 
bioprospecting to drug commercialization), it may certainly be a suitable approach for the initial steps 
of the drug discovery pipeline, namely, while synthetic or semisynthetic alternatives are still being 
technically and financially optimized. Furthermore, the combination of aquaculture practices with a 
variety of techniques to cultivate symbiotic microorganisms appears to be a highly promising approach 
for the discovery of new bioactive compounds from invertebrate-microorganisms assemblages. Culture 
independent methods may also contribute significantly to marine drug discovery [39], either by 
helping to improve microbial cultivation techniques or by producing the target metabolite by 
transgenic organisms able to express the gene responsible for its synthesis. 
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